| Host: |
Goat |
| Applications: |
Pep-ELISA/WB |
| Reactivity: |
Human/Mouse/Rat/Cow/Pig |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Goat polyclonal antibody anti-FBXO32 (Internal) is suitable for use in ELISA and Western Blot research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
| Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Concentration: |
0.5 mg/mL |
| Dilution Range: |
WB-0.3-1µg/mlELISA-antibody detection limit dilution 1:16000. |
| Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
| Gene Symbol: |
FBXO32 |
| Gene ID: |
114907 |
| Uniprot ID: |
FBX32_HUMAN |
| Immunogen Region: |
Internal |
| Accession Number: |
NP_478136.1 |
| Specificity: |
This antibody is expected to recognize reported isoform 1 (NP_478136.1). |
| Immunogen Sequence: |
NSKTKTQYFHQEK |
| Function | Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Probably recognizes and binds to phosphorylated target proteins during skeletal muscle atrophy. Recognizes TERF1. |
| Protein Name | F-Box Only Protein 32Atrogin-1Muscle Atrophy F-Box ProteinMafbx |
| Database Links | Reactome: R-HSA-8951664Reactome: R-HSA-9615017Reactome: R-HSA-983168 |
| Cellular Localisation | CytoplasmNucleusShuttles Between Cytoplasm And The Nucleus |
| Alternative Antibody Names | Anti-F-Box Only Protein 32 antibodyAnti-Atrogin-1 antibodyAnti-Muscle Atrophy F-Box Protein antibodyAnti-Mafbx antibodyAnti-FBXO32 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
